The FDA has approved adalimumab-bwwd (Hadlima, Samsung Bioepis Co.), a biosimilar referencing adalimumab (Humira, AbbVie), for the treatment of adult Crohn’s disease, ulcerative colitis, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis.
Adalimumab-bwwd is Samsung Bioepis’ fourth biosimilar, and third anti-TNF biosimilar, approved in the United States, according to a press release. Approval of the drug was based on